Answers are grounded in this paper and cite their sources.
This was the first study to analyze a large representative population claims database with propensity score matching, and results indicated that follow-up costs of patients treated with MACI and MFX began to converge over time. We found that total costs for MACI were higher than for MFX but that additional costs for MACI were lower than previously reported. Perceived morbidity may have little to do with cost.
No takes yet. Share an insight, caveat, or question.
Niemeyer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: